专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明专利

HUT75164A OPIOID FORMULATIONS HAVING EXTENDED CONTROLLED RELEASE 未知
公开(公告)号：HUT75164A
公开(公告)日：1997-04-28
申请号：HU9401858
申请日：1994-06-21
申请人： EURO CELTIQUE SA
发明人： CHASIN MARK , GOLDENHEIM PAUL , KAIKO ROBERT , OSHLACK BENJAMIN , PEDI FRANK , SACKLER RICHARD
IPC分类号： A61K9/52 , A61K9/16 , A61K9/20 , A61K9/22 , A61K9/28 , A61K9/50 , A61K31/445 , A61K31/485 , A61K31/522 , A61K47/32 , A61K47/36 , A61K47/38 , A61K47/42 , A61K47/44 , A61P25/04
摘要： A solid, controlled release, oral dosage form, the dosage form comprising an analgesically effective amount of an opioid analgesic or a salt thereof, coated with a controlled-release coating or in a controlled-release matrix, wherein the dissolution rate in-vitro of the dosage form, when measured by the USP Paddle Method at 100 rpm at 900 ml aqueous buffer (pH between 1.6 and 7.2) at 37° C is from about 12.5% to about 42.5% (by wt) opioid released after 1 hour, from about 25% to about 65% (by wt) opioid released after 2 hours, from about 45% to about 85% (by wt) opioid released after 4 hours and greater than 60% (by wt) opioid released after 8 hours, the in-vitro release rate being substantially independent of pH and chosen such that the peak plasma level of said opioid obtained in-vivo occurs from about 2 to about 6 hours after administration of the dosage form.

22. 发明专利

IN177789B A process for the preparation of a solid controlled release oral dosage form 未知
公开(公告)号：IN177789B
公开(公告)日：1997-02-22
申请号：IN455CA1994
申请日：1994-06-15
申请人： EURO CELTIQUE SA
发明人： SACKLER RICHARD , OSHLACK BENJAMIN , GOLDENHEIM PAUL , CHASIN MARK , KAIKO ROBERT , PEDI FRANK
IPC分类号： A61K9/30 , A61K9/32 , A61K9/34 , A61K9/56 , A61K9/58 , A61K9/60 , A61K31/485

23. 发明专利

CZ9503217A3 PHARMACEUTICAL PREPARATION AND PROCESS FOR PREPARING THEREOF 未知
公开(公告)号：CZ9503217A3
公开(公告)日：1996-07-17
申请号：CZ321795
申请日：1994-11-22
申请人： EURO CELTIQUE SA
发明人： SACKLER RICHARD , GOLDENHEIM PAUL , KAIKO ROBERT
IPC分类号： A61K9/52 , A61K9/22 , A61K9/50 , A61K9/54 , A61K9/62 , A61K31/485 , A61K45/00 , A61K47/32 , A61K47/38 , A61K47/42 , A61K47/44 , A61K47/46 , A61P25/04 , A61K9/14
CPC分类号： A61K9/5078 , A61K9/2081 , A61K9/4808 , A61K9/5026 , A61K9/5073 , A61K31/485

24. 发明专利

CZ321795A3 PHARMACEUTICAL PREPARATION AND PROCESS FOR PREPARING THEREOF 未知
公开(公告)号：CZ321795A3
公开(公告)日：1996-07-17
申请号：CZ321795
申请日：1994-11-22
申请人： EURO CELTIQUE SA
发明人： SACKLER RICHARD , GOLDENHEIM PAUL , KAIKO ROBERT
IPC分类号： A61K9/52 , A61K9/22 , A61K9/50 , A61K9/54 , A61K9/62 , A61K31/485 , A61K45/00 , A61K47/32 , A61K47/38 , A61K47/42 , A61K47/44 , A61K47/46 , A61P25/04 , A61K9/14
摘要： Oral sustained release opioid formulation comprises: an opioid analgesic, a retardant material to cause the opioid analgesic to be released at a rate to provide an analgesic effect after oral admin. to a human patient for 24 hrs, the formulation when administered in humans providing an initially rapid rate of rise in the plasma conc. of the opioid characterised by providing an absorption half-life of 1-8 hrs. in the fastened state. Method for titrating human patients with a sustained release oral opioid formulation comprises: 1) administering to a human patient on a once-a-day basis a unit dose of an oral sustained release formulation comprising a dose of an opioid analgesic and a retardant material as described above, 2) monitoring pharmacokinetic and pharmacodynamic parameters elicited by the formulation in the human patient and determining whether the pharmacokinetic and/or pharmacodynamic parameters are appropriate to treat the patient on a repeated basis, 3) titrating t he patient by adjusting the dose of the opioid analgesic administered to the patient by administering a unit dose of the sustained release opioid analgesic formulation if it is determined that the pharmacokinetic and/or the pharmacodynamic parameters are not satisfactory or maintaining the dose of the opioid analgesic in the unit dose at a previously administered amt. if the pharmacokinetic and/or pharmacodynamic parameters are deemed appropriate, 4) continuing the step 3 titration by adjusting the dose of the opioid analgesic until appropriate steady state pharmacokinetic and/or pharmacodynamic parameters are achieved in the patient, and 5) continuing the admin. of the dose of the opioid analgesic in the oral sustained release formulation on a once-a-day basis until treatment is terminated.

26. 发明专利

ZA9404599B Opioid formulations having extended controlled release 未知
公开(公告)号：ZA9404599B
公开(公告)日：1995-02-14
申请号：ZA9404599
申请日：1994-06-27
申请人： EURO CELTIQUE SA
发明人： SACKLER RICHARD , GOLDENHEIM PAUL , KAIKO ROBERT , OSHLACK BENJAMIN , CHASIN MARK , PEDI FRANK
IPC分类号： A61K9/52 , A61K9/16 , A61K9/20 , A61K9/22 , A61K9/28 , A61K9/50 , A61K31/445 , A61K31/485 , A61K31/522 , A61K47/32 , A61K47/36 , A61K47/38 , A61K47/42 , A61K47/44 , A61P25/04 , A61K
CPC分类号： A61K9/1635 , A61K9/1617 , A61K9/2013 , A61K9/2054 , A61K9/2072 , A61K9/2081 , A61K9/2095 , A61K9/2866 , A61K9/5078 , A61K31/485 , A61K31/522

27. 发明专利

PL304062A1 RETARDED RELEASE COMPOSITIONS AND METHOD OF OBTAINING SUCH COMPOSITIONS 未知
公开(公告)号：PL304062A1
公开(公告)日：1995-01-09
申请号：PL30406294
申请日：1994-06-30
申请人： EURO CELTIQUE SA
发明人： HEAFIELD JOANNE , KNOTT TREVOR JOHN , LESLIE STEWART THOMAS , MALKOWSKA SANDRA THERESE A , MILLER RONALD BROWN , PRATER DEREK ALLAN , SMITH KEVIN JOHN , CHASIN MARK , GOLDENHEIM PAUL , OSHLACK BENJAMIN , PEDI FRANK JR , SACKLER RICHARD , KAIKO ROBERT
IPC分类号： A61K9/22 , A61K9/16 , A61K9/20 , A61K9/28 , A61K9/50 , A61K9/52 , A61K31/135 , A61K31/137 , A61K31/485 , A61K31/522 , A61K47/44 , A61P25/04
摘要： In order to provide a sustained release pharmaceutical formulation containing morphine which is suitable for administration on a once daily basis, in a first aspect, an orally administrable sustained release dosage unit form contains morphine, or a pharmaceutically acceptable salt thereof, as active ingredient, which formulation gives a peak plasma level at 1.0 to 6 hours after administration. In a second aspect, the formulation contains an effective amount of morphine or a pharmaceutically acceptable salt thereof, characterised by a W50 for the M-6-G metabolite or for morphine of between 4 and 12 hours. In a third aspect, the pharmaceutical dosage unit form is obtainable by compressing multiparticulates comprising a pharmaceutically active substance in a matrix of hydrophobic fusible material having a melting point of from 35 to 150 DEG C, the dosage form optionally containing conventional tabletting excipients. In a further aspect of the invention, sustained release multiparticulates containing morphine or a pharmaceutically acceptable salt thereof are produced by mechanically working in a high-speed mixer a mixture of particulate morphine or a pharmaceutically acceptable salt thereof and a particulate, hydrophobic fusible carrier or diluent having a melting point from 35 to 150 DEG C and optionally a release control component comprising a water soluble fusible material or a particulate soluble or insoluble organic or inorganic material at a speed and energy input which allows the carrier or diluent to melt or soften whereby it agglomerates, and breaking down the agglomerates to give controlled release particles.

28. 发明专利

AT556682T 未知
公开(公告)号：AT556682T
公开(公告)日：2012-05-15
申请号：AT10185240
申请日：1998-02-24
申请人： EURO CELTIQUE SA
发明人： REDER ROBERT , GOLDENHEIM PAUL , KAIKO ROBERT
IPC分类号： A61F13/00 , A61K9/22 , A61K9/70 , A61K31/00 , A61K31/485 , A61P25/00 , A61P25/04 , A61P29/00
摘要： A sustained release formulation of buprenorphine is new. The composition comprises a transdermal delivery device which provides a first order release of buprenorphine over a 3-day dosing interval so that a maximum plasma concentration of 20 10 1052 pg/ml is obtained. the device then provides zero order kinetics over at least 2 more days.

29. 发明专利

ES2380023T3 Parche transdérmico de buprenorfina para ser usado en el tratamiento del dolor para un intervalo de dosificación de por lo menos 4 días 未知
公开(公告)号：ES2380023T3
公开(公告)日：2012-05-07
申请号：ES05011213
申请日：1998-02-24
申请人： EURO CELTIQUE SA
发明人： REDER ROBERT , GOLDENHEIM PAUL , KAIKO ROBERT
IPC分类号： A61F13/00 , A61K9/22 , A61K9/70 , A61K31/00 , A61K31/485 , A61P25/00 , A61P25/04 , A61P29/00
摘要： Sistema de administración transdérmica de buprenorfina que comprende una capa de matriz polimérica que incluye buprenorfina o una sal farmacéuticamente aceptable de la misma y una capa de refuerzo realizada con un material farmacéuticamente aceptable que es impermeable a la buprenorfina, en donde el sistema de administración transdérmica comprende un 10% en peso de base de buprenorfina, entre un 10 y un 15% en peso de ácido levulínico, aproximadamente un 10% en peso de oleiloleato, entre un 55 y un 70% en peso de poliacrilato y entre un 0 y un 10% en peso de polivinilpirrolidona, para su uso en el tratamiento del dolor en un paciente humano durante un intervalo de dosificación de por lo menos 4 días, en donde dicho sistema de administración transdérmica proporciona durante el intervalo de dosificación de aproximadamente 72 horas una velocidad de liberación de buprenorfina tal que se logra una concentración plasmática máxima de entre 20 pg/ml y 850 pg/ml, y el sistema de administración transdérmica, cuando se mantiene sobre la piel del paciente durante el intervalo de dosificación de por lo menos 24 horas adicionales, proporciona concentraciones plasmáticas de buprenorfina en los pacientes por encima de las concentraciones efectivas mínimas de la buprenorfina, de tal modo que los pacientes continúan experimentando una gestión eficaz del dolor durante este intervalo de dosificación adicional.

30. 发明专利

AT538765T 未知
公开(公告)号：AT538765T
公开(公告)日：2012-01-15
申请号：AT05011213
申请日：1998-02-24
申请人： EURO CELTIQUE SA
发明人： REDER ROBERT , GOLDENHEIM PAUL , KAIKO ROBERT
IPC分类号： A61F13/00 , A61K9/22 , A61K9/70 , A61K31/00 , A61K31/485 , A61P25/00 , A61P25/04 , A61P29/00
摘要： A sustained release formulation of buprenorphine is new. The composition comprises a transdermal delivery device which provides a first order release of buprenorphine over a 3-day dosing interval so that a maximum plasma concentration of 20 10 1052 pg/ml is obtained. the device then provides zero order kinetics over at least 2 more days.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式